Bio Green Med Solution (BGMS)
NASDAQ:BGMS
Want to see BGMS full AI Analyst Report?
BGMS Stock Chart & Stats
$1.45
--
Market closed
$1.45
--
Day’s Range― - ―
52-Week Range$0.73 - $83.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)473.94K
Market Cap
$5.52M
Enterprise Value-$1.32M
Total Cash (Recent Filing)$3.50M
Total Debt (Recent Filing)$2.00K
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.27%
Share Statistics
EPS (TTM)-4.45
Shares Outstanding5,519,456
10 Day Avg. Volume1,252,948
30 Day Avg. Volume473,939
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.24
Enterprise Value/Revenue-1.77
Enterprise Value/Gross Profit-9.63
Enterprise Value/Ebitda0.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Strategic Pivot To Fire Safety DistributionThe company’s exit from legacy biopharma and refocus on fire safety distribution creates a simpler, lower-capital business model. This reduces high R&D burn, shifts toward recurring product sales and distribution margins, and lowers execution risk versus drug development over the medium term.
Acquisition-driven Revenue ReboundThe Fitters acquisition immediately delivered measurable revenue and helped lift 2025 top-line to $0.75M from $0.04M. Tangible post-acquisition sales validate the new operating model, showing early commercial traction and a foundation to scale recurring distribution revenue over coming quarters.
Low Leverage And Reported Equity BufferVery low debt and a reported equity cushion provide financial flexibility, lowering solvency risk and extending runway. With modest liabilities, management has more options for restructuring, targeted investments, or capital raises without immediate distress, benefiting long-term stability.
Bears Say
Consistent Negative Operating And Free Cash FlowRepeated, sizable negative OCF and FCF across multiple years indicate the business cannot self-fund operations or growth. Ongoing cash burn forces reliance on external financing, raising dilution and refinancing risk, and constraining durable investment in inventory, sales, or distribution expansion.
Multi-year Operating Losses And Weak ProfitabilityPersistent operating losses and wide negative EBIT reflect structural lack of operating leverage. Even with revenue improvement, the firm has yet to demonstrate sustainable margins or break-even economics, which impedes capital formation and raises uncertainty about a durable path to profitability.
Preferred Share Delisting Reduces LiquidityNasdaq delisting of the preferred stock materially reduces market liquidity and investor access to that tranche. This impairs price discovery, complicates capital structure management, and can increase future financing costs or investor reluctance to provide capital, a lasting structural headwind.
Bio Green Med Solution News
BGMS FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was $0.73 and its highest was $83.28 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is $5.52M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is May 13, 2026 which is in 5 days.
How were Bio Green Med Solution’s earnings last quarter?
Bio Green Med Solution released its earnings results on Mar 30, 2026. The company reported -$2.21 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.21.
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution pays a Notavailable dividend of $0.15 which represents an annual dividend yield of 10.27%. See more information on Bio Green Med Solution dividends here
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 5,519,456 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Bio Green Med Solution reported an EPS of -$2.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.842%.
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in BGMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―
Ownership Overview
57.05% Insiders
0.03% Mutual Funds
<0.01% Other Institutional Investors
42.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---